Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding Ltd
(OP:
RHHVF
)
332.65
+0.89 (+0.27%)
Streaming Delayed Price
Updated: 2:16 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding Ltd
< Previous
1
2
3
4
5
6
7
Next >
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic
July 22, 2021
Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped...
Via
Benzinga
Exposures
COVID-19
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
July 21, 2021
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in...
Via
Benzinga
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
July 21, 2021
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with...
Via
Benzinga
Exposures
Product Safety
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
July 19, 2021
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A...
Via
Benzinga
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
July 12, 2021
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold...
Via
Benzinga
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients
July 07, 2021
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients...
Via
Benzinga
Exposures
COVID-19
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients
June 30, 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-...
Via
Benzinga
Exposures
COVID-19
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
June 29, 2021
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
June 28, 2021
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...
Via
Benzinga
Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder
June 28, 2021
The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder...
Via
Benzinga
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19
June 25, 2021
The
Via
Benzinga
Exposures
Product Safety
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows
June 22, 2021
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's...
Via
Benzinga
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod
June 18, 2021
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat...
Via
Benzinga
Exposures
COVID-19
Product Safety
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
June 17, 2021
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway...
Via
Benzinga
Exposures
Product Safety
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
June 17, 2021
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic...
Via
Benzinga
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
June 16, 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license...
Via
Benzinga
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients
June 14, 2021
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/...
Via
Benzinga
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
June 11, 2021
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ...
Via
Benzinga
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
June 07, 2021
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting...
Via
Benzinga
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer
June 04, 2021
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti...
Via
Benzinga
Biogen, Bio-Thera's Biosimilar Referencing Tocilizumab Meets Primary Endpoints In Late-Stage Study
June 01, 2021
Biogen Inc (NASDAQ: BIIB) and China's Bio-Thera Solutions Ltd have announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing...
Via
Benzinga
AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia
May 25, 2021
The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid...
Via
Benzinga
Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings
May 25, 2021
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ...
Via
Benzinga
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
May 25, 2021
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination...
Via
Benzinga
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
May 20, 2021
I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY)...
Via
Benzinga
Roche's Cobas COVID Test Scores EUA For Asymptomatic People
May 18, 2021
Roche Holdings AG’s (OTC: RHHBY) Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID...
Via
Benzinga
Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing
May 11, 2021
Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early...
Via
Benzinga
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail
May 05, 2021
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for...
Via
Benzinga
Exposures
COVID-19
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer
April 29, 2021
The FDA’s Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval...
Via
Benzinga
Exposures
Product Safety
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
April 29, 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.